This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Institutional Stock Ownership and Shareholders()
Frontier Communications Corp. (NASDAQ:FTR) has 31 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82,025,541 shares.
Largest shareholders include
BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Group LTD, BlackRock Investment Management, LLC, BlackRock Advisors LLC, PVG Asset Management, BlackRock Japan Co. Ltd, Aberdeen Asset Management Plc/uk, R&F Capital Advisors LP, and Thrax Management, LLC.
Frontier Communications Corp. (NASDAQ:FTR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ftr"><img src="https://images.fintel.io/us-ftr-so.png" alt="FTR / Frontier Communications Corp. Institutional Ownership"><a>
|BlackRock Fund Advisors||25,173,459||27,408,865||8.88||104,722||92,642||-11.54|
|R&F Capital Advisors LP||95,054||501,638||427.74||321||1,074||234.58|
|Camelot Portfolios, LLC||75,108||0||-100.00||508||0||-100.00|
|PVG Asset Management||1,656,750||5,599,815|
|CAPSTONE ASSET MANAGEMENT CO||72,234||44,978||-37.73||155||52||-66.45|
|Concert Wealth Management Inc.||11,456||0||-100.00||38||0||-100.00|
|Spot Trading L.L.C||0||4,558||0||10|
|Spot Trading L.L.C||Put||53,100||114|
|Vantage Investment Advisors, LLC||2,131||2,129||-0.09||14||16||14.29|
|PVG ASSET MANAGEMENT CORP||119,425||0||-100.00||807,313||0||-100.00|
|BlackRock Institutional Trust Company, N.A.||32,908,876||33,915,267||3.06||136,901||114,634||-16.27|
|BlackRock Japan Co. Ltd||1,401,366||1,414,516||0.94||5,830||4,781||-17.99|
|Thrax Management, LLC||Put||220,000||744|
|WHITTIER TRUST CO||0||650||0||4|
|Fore Research & Management, LP||160,000||105,000||-34.38||342||121||-64.62|
|ABERDEEN ASSET MANAGEMENT PLC/UK||367,279||706,048||92.24||786||819||4.20|
|WFG Advisors, LP||50,026||0||-100.00||107||0||-100.00|
|MASON STREET ADVISORS, LLC||158,690||660|
|Gemmer Asset Management LLC||8||8||0.00||0||0|
|CT Financial Advisors LLC||2,500||2,500||0.00||8,450||5,350||-36.69|
|ORRSTOWN FINANCIAL SERVICES INC||0||480||0||1|
|Commonwealth Equity Services, Inc||298,398||0||-100.00||346||0||-100.00|
|KANALY TRUST CO||259||1|
|BlackRock Group LTD||11,642,719||11,363,837||-2.40||48,434||38,410||-20.70|
|Mizuho Asset Management Co.,Ltd.||94,533||94,533||0.00||467||393||-15.85|
|JANUS CAPITAL MANAGEMENT LLC||252,546||43,900||-82.62||853||94||-88.98|
|Spot Trading L.l.c.||Put||64,600||75|
|Nelson Roberts Investment Advisors, LLC||0||8||0||0|
|Sterling Investment Advisors, Ltd.||8||8||0.00||0||0|
|ARXIS SECURITIES LLC||11,860||0||-100.00||40||0||-100.00|
|BlackRock Investment Management, LLC||2,642,910||2,725,197||3.11||10,995||9,211||-16.23|
|Spot Trading L.l.c.||26,453||31|
|RONALD BLUE & CO LLC||17,756||0||-100.00||38||0||-100.00|
|HIGH POINT BANK & TRUST CO||1,006||1,006||0.00||4||4||0.00|
|MetLife Securities, Inc||134,496||117,137||-12.91||559||396||-29.16|
|FIRST FINANCIAL EQUITY CORPORATION||10,110||20|
|Spot Trading L.L.C||Call||28,000||60|
|UNITED FIRE GROUP INC||859||658||-23.40||6||5||-16.67|
|BlackRock Advisors LLC||1,539,589||1,719,663||11.70||6,405||5,813||-9.24|
|Alpha Omega Wealth Management LLC||20||0||-100.00||0||0|
|Spot Trading L.l.c.||Call||17,000||20|
|Focused Wealth Management, Inc||216||204||-5.56||1||2||100.00|
2018-03-04 - Asif
Business Frontier Communications Corporation (Frontier) is a provider of communications services in the United States, with approximately 4.9 million customers, 3.9 million broadband subscribers and 22,700 employees, operating in 29 states. In recent years, Frontier has completed multiple acquisitions. On April 1, 2016, the company acquired the wireline operations of Verizon Communications, Inc. in California, Texas and Florida for a purchase price of $10,540 million in cash and assumed debt. The company conduct business with both consumer and commercial customers. Consumer. The company provide broadband, video, voice and other services and products to its consumer customers. The company deliver these services generally over a combination of fiber and copper-based networks. Commercial (small, medium and large enterprise business (SME) as well as wholesale customers). Com...
8h - Asif
Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
Related News Stories
Comstock Resources, Inc. (CRK - Free Report) : This independent energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 17.1% over the last 60 days. (15-1)
There is no incredible value created by the series of articles covering fixed income products whose Call Option was finally, or perhaps timely, exercised by the issuing company. However, it turns out that not all of us have the resources and time to keep track of their portfolio, thus we are continuing our coverage of these events. (8-0)
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. (24-0)
Grupo Simec, S.A.B. de C.V. (SIM - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 17.1% in the past one-month time frame. (17-0)
Investors are always looking for stocks that are poised to beat at earnings season E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (18-0)
as of ET